Serban-Dan Costa
Research Subjects
Research Interests
Serban-Dan Costa has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Atanas Ignatov
University Hospital for Obstetrics and Gynecology, Medical Faculty, Otto-von-Guericke University, 39108 Magdeburg, Germany
4 shared publications Albert Roessner
Otto-von-Guericke University
2 shared publications- Gunter von Minckwitz
German Breast Group, Neu-Isenburg, Germany
2 shared publications - Holm Eggemann
Universitätsfrauenklinik Magdeburg, Magdeburg, Deutschland
2 shared publications Joachim Bischoff
Otto-von-Guericke University
2 shared publications- Sibylle Loibl
German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany
2 shared publications
Latest Publications
- 6 November 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 300 (6) , 1591-1600
The impact of neuropsychiatric disease on fetal growth: a case–control study
To determine the impact of depression, epilepsy and drug abuse during pregnancy on delivery and fetal outcome. Due to the worldwide increasing prevalence of neurological and psychiatric diseases and drug abuse, the number of affected pregnant women is increasing.
- 6 November 2019
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 300 (6) , 1591-1600
The impact of neuropsychiatric disease on fetal growth: a case–control study
To determine the impact of depression, epilepsy and drug abuse during pregnancy on delivery and fetal outcome. Due to the worldwide increasing prevalence of neurological and psychiatric diseases and drug abuse, the number of affected pregnant women is increasing.
- 2 April 2018
- Published by Springer Nature in Uro-News
- Vol. 22 (4) , 32-37
Von guten und schlechten Ärzten — die neue Realität medizinischer Versorgung
- 2 April 2018
- Published by Springer Nature in Uro-News
- Vol. 22 (4) , 32-37
Von guten und schlechten Ärzten — die neue Realität medizinischer Versorgung
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18121
Quality of patient-reported outcome for long-term survival of early breast cancer trials.
E18121 Background: Follow up (FU) of long term survival in early breast cancer (BC) trials is highly important as treatment effects might change over time and have to be related to late or chronic toxicities. In countries without access to national cancer registries, collection of long term FU is often an unaccomplishable task due to the logistic and financial burden for study sites and sponsors. Patient-reported outcome (PRO) registries for long term FU, like the one established by the German Breast Group (GBG) (von Minckwitz Eur J Cancer 2012) might be an accomplishable option for data collection. Here, we analyzed the quality of the PRO by validation with data provided by the investigators. Methods: Since 2009 almost 6000 participants of GBG trials joined PRO, consenting for name, address, and unique study identifier to be collected by a trustee who sent pseudonymized questionnaires about basic health status approx. once per year. PRO data of 5417 patients from 18 trials with a total of 396 reported events, including deaths (2.5%) and relapses/2nd malignancies (5%), and with no answer/withdrawal (14%), was sent for validation to 210 sites. Results: We received answers from 67 (32%) sites with feedback on 1161 (21%) patients. Sites confirmed the PRO result in 675 (58%) cases. Sites provided more recent data for 210 (18%) patients (including 43 new events), specified a missing event date for 6 (0.5%) patients, changed the diagnosis for 1 patient (from 2nd malignancy to metastasis), had not data available for 262 (23%) patients, or reported contradictory results for 5 (0.4%) patients (1 under- and 4 over-reported events in PRO). Sites were able to provide information for 157/228 (70%) patients not answering via PRO (reporting 24 new events). Sites giving feedback did not know about 6% (10 of 176) of the events reported by PRO. Conclusions: PRO seems to provide valid as well as additional information on disease-free and overall survival of BC patients at much lower costs and effort. Combination of PRO with focused effort by the site on those patients not answering or reporting incomplete data is a practical and valid approach to obtain FU data.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18121
Quality of patient-reported outcome for long-term survival of early breast cancer trials.
E18121 Background: Follow up (FU) of long term survival in early breast cancer (BC) trials is highly important as treatment effects might change over time and have to be related to late or chronic toxicities. In countries without access to national cancer registries, collection of long term FU is often an unaccomplishable task due to the logistic and financial burden for study sites and sponsors. Patient-reported outcome (PRO) registries for long term FU, like the one established by the German Breast Group (GBG) (von Minckwitz Eur J Cancer 2012) might be an accomplishable option for data collection. Here, we analyzed the quality of the PRO by validation with data provided by the investigators. Methods: Since 2009 almost 6000 participants of GBG trials joined PRO, consenting for name, address, and unique study identifier to be collected by a trustee who sent pseudonymized questionnaires about basic health status approx. once per year. PRO data of 5417 patients from 18 trials with a total of 396 reported events, including deaths (2.5%) and relapses/2nd malignancies (5%), and with no answer/withdrawal (14%), was sent for validation to 210 sites. Results: We received answers from 67 (32%) sites with feedback on 1161 (21%) patients. Sites confirmed the PRO result in 675 (58%) cases. Sites provided more recent data for 210 (18%) patients (including 43 new events), specified a missing event date for 6 (0.5%) patients, changed the diagnosis for 1 patient (from 2nd malignancy to metastasis), had not data available for 262 (23%) patients, or reported contradictory results for 5 (0.4%) patients (1 under- and 4 over-reported events in PRO). Sites were able to provide information for 157/228 (70%) patients not answering via PRO (reporting 24 new events). Sites giving feedback did not know about 6% (10 of 176) of the events reported by PRO. Conclusions: PRO seems to provide valid as well as additional information on disease-free and overall survival of BC patients at much lower costs and effort. Combination of PRO with focused effort by the site on those patients not answering or reporting incomplete data is a practical and valid approach to obtain FU data.
- Open Access
- 14 July 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 517
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)
Liver metastases from breast cancer (LMBC) are typically considered to indicate systemic disease spread and patients are most often offered systemic palliative treatment only. However, retrospective studies suggest that some patients may have improved survival with local treatment of their liver metastases compared to systemic therapy alone. In the absence of randomized trials, it is important to identify patient characteristics indicating that benefit from local treatment can be expected. 59 patients undergoing radiofrequency ablation (RFA), interstitial brachytherapy (BT), or radioembolization (RE) of LMBC as a salvage treatment were studied. Potential factors influencing survival were analyzed in a multivariate Cox model. For factors identified to have an independent survival impact, Kaplan-Meier analysis and comparison of overall survival (OS) using the log-rank test was performed. Median OS following local interventional treatment was 21.9 months. Considering only factors evaluable at treatment initiation, maximum diameter of liver metastases (≥3.9 cm; HR: 3.1), liver volume (≥ 1376 mL; HR: 2.3), and history of prior chemotherapy (≥ 3 lines of treatment; HR: 2.5-2.6) showed an independent survival impact. When follow-up data were included in the analysis, significant factors were maximum diameter of liver metastases (≥ 3.9 cm; HR: 3.1), control of LMBC during follow-up (HR: 0.29), and objective response as best overall response (HR: 0.21). Neither the presence of any extrahepatic metastases nor presence of bone metastases only had a significant survival impact. Median OS was 38.7 vs. 16.1 months in patients with metastases < vs. ≥ 3.9 cm, 36.6 vs. 10.2 months for patients having objective response vs. stable/progressive disease, and 38.5 vs. 14.2 months for patients having controlled vs. non-controlled disease at follow-up. Local control of LMBC confers a survival benefit and local interventional treatment for LMBC should be studied in a randomized trial. Patients with small metastases and limited history of systemic LMBC treatment are most likely to benefit from local approaches. Limited extrahepatic disease should not lead to exclusion from a randomized study and should not be a contraindication for local LMBC treatment as long as no randomized data are available.
- 14 July 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 517
Open AccessLocally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)
Liver metastases from breast cancer (LMBC) are typically considered to indicate systemic disease spread and patients are most often offered systemic palliative treatment only. However, retrospective studies suggest that some patients may have improved survival with local treatment of their liver metastases compared to systemic therapy alone. In the absence of randomized trials, it is important to identify patient characteristics indicating that benefit from local treatment can be expected. 59 patients undergoing radiofrequency ablation (RFA), interstitial brachytherapy (BT), or radioembolization (RE) of LMBC as a salvage treatment were studied. Potential factors influencing survival were analyzed in a multivariate Cox model. For factors identified to have an independent survival impact, Kaplan-Meier analysis and comparison of overall survival (OS) using the log-rank test was performed. Median OS following local interventional treatment was 21.9 months. Considering only factors evaluable at treatment initiation, maximum diameter of liver metastases (≥3.9 cm; HR: 3.1), liver volume (≥ 1376 mL; HR: 2.3), and history of prior chemotherapy (≥ 3 lines of treatment; HR: 2.5-2.6) showed an independent survival impact. When follow-up data were included in the analysis, significant factors were maximum diameter of liver metastases (≥ 3.9 cm; HR: 3.1), control of LMBC during follow-up (HR: 0.29), and objective response as best overall response (HR: 0.21). Neither the presence of any extrahepatic metastases nor presence of bone metastases only had a significant survival impact. Median OS was 38.7 vs. 16.1 months in patients with metastases < vs. ≥ 3.9 cm, 36.6 vs. 10.2 months for patients having objective response vs. stable/progressive disease, and 38.5 vs. 14.2 months for patients having controlled vs. non-controlled disease at follow-up. Local control of LMBC confers a survival benefit and local interventional treatment for LMBC should be studied in a randomized trial. Patients with small metastases and limited history of systemic LMBC treatment are most likely to benefit from local approaches. Limited extrahepatic disease should not lead to exclusion from a randomized study and should not be a contraindication for local LMBC treatment as long as no randomized data are available.
- 1 August 2014
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 74 (08) , 707-709
Leserbrief. Warum wir anstelle einer Zertifizierung von Perinatalzentren neue Strukturen brauchen
H. Stepan und seine drei Koautoren führen in ihrem Bericht (Geburtsh Frauenheilk 2014; 74: 323–324) einige Argumente an, um die Notwendigkeit eines Zertifizierungsprozesses von Perinatalzentren zu begründen. Beispielhaft werden die Brustzentren als „Erfolgsmodell“ angegeben und die „Kontrolle der Standards durch den GBA und MDK“ (!) gelobt, aber als nicht ganz ausreichend bezeichnet. Es wird auch die „forensische Komponente“ erwähnt, wobei mit einer „Sicht von außen“ die Hoffnung verbunden wird, „Schadensfälle zu vermeiden“. Wie bei allen Zertifizierungsverfahren soll sich das von Stepan und Kollegen vorgeschlagene Zertifizierungsverfahren nicht auf eine einmalige Momentaufnahme beschränken, sondern als dynamischer Prozess Perinatalzentren über viele Jahre begleiten.
- 1 August 2014
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 74 (08) , 707-709
Leserbrief. Warum wir anstelle einer Zertifizierung von Perinatalzentren neue Strukturen brauchen
H. Stepan und seine drei Koautoren führen in ihrem Bericht (Geburtsh Frauenheilk 2014; 74: 323–324) einige Argumente an, um die Notwendigkeit eines Zertifizierungsprozesses von Perinatalzentren zu begründen. Beispielhaft werden die Brustzentren als „Erfolgsmodell“ angegeben und die „Kontrolle der Standards durch den GBA und MDK“ (!) gelobt, aber als nicht ganz ausreichend bezeichnet. Es wird auch die „forensische Komponente“ erwähnt, wobei mit einer „Sicht von außen“ die Hoffnung verbunden wird, „Schadensfälle zu vermeiden“. Wie bei allen Zertifizierungsverfahren soll sich das von Stepan und Kollegen vorgeschlagene Zertifizierungsverfahren nicht auf eine einmalige Momentaufnahme beschränken, sondern als dynamischer Prozess Perinatalzentren über viele Jahre begleiten.
- 29 January 2014
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 74 (01) , 46-49
Mastitis. Brustentzündungen
Die Mastitis ist eine in den meisten Fällen akute Entzündung der weiblichen und selten der männlichen Brustdrüse. Die Brustentzündung bei Frauen wird grundsätzlich unterteilt in die
- 29 January 2014
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 74 (01) , 46-49
Mastitis. Brustentzündungen
Die Mastitis ist eine in den meisten Fällen akute Entzündung der weiblichen und selten der männlichen Brustdrüse. Die Brustentzündung bei Frauen wird grundsätzlich unterteilt in die
- Open Access
- 29 May 2013
- Published by Springer Nature in Der Onkologe
- Vol. 19 (6) , 446-447
Beim Brustkrebs nichts Neues …
- 29 May 2013
- Published by Springer Nature in Der Onkologe
- Vol. 19 (6) , 446-447
Open AccessBeim Brustkrebs nichts Neues …
- 9 December 2012
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 137 (2) , 465-470
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen (N = 207) or aromatase inhibitors (N = 50). The median follow-up was 42.2 (range 2–115) months. Median age at diagnosis was 68 (range 36–91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient’s age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13–2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.
- 9 December 2012
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 137 (2) , 465-470
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen (N = 207) or aromatase inhibitors (N = 50). The median follow-up was 42.2 (range 2–115) months. Median age at diagnosis was 68 (range 36–91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient’s age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13–2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.
- Open Access
- 24 September 2012
- Published by Springer Nature in BMC Gastroenterology
- Vol. 12 (1) , 131
A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy
Symptoms of gastro-esophageal reflux disease (GERD) in pregnancy are reported with a prevalence of 30–80%. The aim of this study was to assess the prevalence and severity of GERD symptoms during the course of pregnancy. Furthermore current practice in medical care for GERD during pregnancy was assessed.
- 24 September 2012
- Published by Springer Nature in BMC Gastroenterology
- Vol. 12 (1) , 131
Open AccessA prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy
Symptoms of gastro-esophageal reflux disease (GERD) in pregnancy are reported with a prevalence of 30–80%. The aim of this study was to assess the prevalence and severity of GERD symptoms during the course of pregnancy. Furthermore current practice in medical care for GERD during pregnancy was assessed.